A
Power Law company profile
Ablynx
Biotech & Life Sciences · Ghent, Belgium · Founded 2001 · IPO 2007 Unicorn
Valuation
$4.29B
Market cap · 2026
Revenue
$135M
Latest reported FY
Global footprint
Where Ablynx has talent and traffic
Web traffic by country
180
monthly visits
across markets
across markets
🇫🇷 France111.1%
Patent intelligence
$2B patent portfolio · 1,356 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$2B
47.3% of market cap · 2.6× the top peer BioNTech ($780M)
1,356 active patent families
Where Ablynx innovates
Molecular biologyPharmaceutical drugDiseaseNucleic acidGlobulin
Below peer median on Legal, Strategic, Market, Technology
Quality vs same-sector peers
Ablynx on the five Patsnap quality dimensions
Ablynx in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Ablynx concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Ablynx and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Ablynx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.